ArticleJAMA network open2024

International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.

Samuel A Kareff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.